Trial · NCT03355664
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Polymerase Chain Reaction Corrected Efficacy Defined as Adequate Clinical and Parasitological Response (ACPR) by Study Arm | Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 146 | Participants | ||
| Polymerase Chain Reaction Corrected Efficacy Defined as Adequate Clinical and Parasitological Response (ACPR) by Study Arm | Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 151 | Participants | ||
| 42-day Polymerase Chain Reaction Corrected Efficacy According to Site/Geographic Region | Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | West Cambodia | 32 | Participants | |
| 42-day Polymerase Chain Reaction Corrected Efficacy According to Site/Geographic Region | Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | West Cambodia | 35 | Participants | |
| 42-day Polymerase Chain Reaction Corrected Efficacy According to Site/Geographic Region | Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | East Cambodia | 91 | Participants | |
| 42-day Polymerase Chain Reaction Corrected Efficacy According to Site/Geographic Region | Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | East Cambodia | 90 | Participants | |
| 42-day Polymerase Chain Reaction Corrected Efficacy According to Site/Geographic Region | Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | Vietnam | 23 | Participants | |
| 42-day Polymerase Chain Reaction Corrected Efficacy According to Site/Geographic Region | Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | Vietnam | 26 | Participants | |
| Parasite Clearance Half-life | Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 5 | Standard Deviation 2.5 | Hours | |
| Parasite Clearance Half-life | Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 5.5 | Standard Deviation 2.6 | Hours | |
| Fever Clearance Time | Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 18.3 | Standard Deviation 12.6 | Hours to fever clearance | |
| Fever Clearance Time | Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 14.9 | Standard Deviation 9.9 | Hours to fever clearance | |
| Number of Severe Adverse Events by Study Arm | Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 2 | Participants | ||
| Number of Severe Adverse Events by Study Arm | Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 5 | Participants | ||
| Incidence of Adverse Events Concerning Markers of Hepatic or Renal Toxicity | Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 53 | Events | ||
| Incidence of Adverse Events Concerning Markers of Hepatic or Renal Toxicity | Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 63 | Events | ||
| Incidence of Prolongation of the Corrected QT Interval | Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 0 | Events | ||
| Incidence of Prolongation of the Corrected QT Interval | Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 0 | Events | ||
| Prolongation of the Corrected QT Interval | Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 | 0 | Events | ||
| Prolongation of the Corrected QT Interval | Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24 | 0 | Events |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03355664/results